Product Description
The 1B1.3A monoclonal antibody reacts with mouse IL-10R (IL-10 receptor) also known as CD210. The IL-10R is a class II cytokine receptor and is expressed by a variety of cell types including thymocytes, T lymphocytes, B lymphocytes, NK cells, monocytes, and macrophages. Upon binding IL-10, IL-10R stimulation results in many pleiotropic, effects in immunoregulation and inflammation. IL-10R downregulates the expression of pro-inflammatory cytokines, MHC class II antigens, and co-stimulatory molecules on macrophages. It also enhances B lymphocyte survival, proliferation, and antibody production. IL-10R signaling can block NF-kappaB activity, and is involved in the regulation of the JAK-STAT signaling pathway. The 1B1.3A antibody is a neutralizing antibody and has been shown to block the binding of human IL-10, which cross-reacts with the mouse IL-10R. However, this clone does not recognize the human IL-10R. Bio X Cell is pleased to offer two recombinant, murine chimeric versions of the original 1B1.3A antibody, 1B1.3A-CP060 and 1B1.3A-CP073. The variable region sequences are identical to the original 1B1.3A but the constant region sequences have been switched from Rat IgG1, kappa to mouse IgG2a, kappa for use in murine models. Species-matched chimeric antibodies exhibit regulated effector functions-including Fc receptor binding and complement activation-and cause less immunogenicity and formation of anti-drug antibodies (ADAs) than xenogenic antibodies in animal models. Additionally, 1B1.3A-CP073 contains LALA-PG Fc-silencing mutations in the heavy chain rendering it unable to bind endogenous murine FcgammaR or C1q to induce antibody-dependent, cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). Antibodies with active Fc regions can engage immune cells via FcgammaRs, leading to the depletion of antigen expressing cells through mechanisms like ADCC or complement activation. Fc-silenced antibodies do not trigger these pathways and can block signaling without killing or depleting target cells. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies.
* VAT and shipping costs not included. Errors and price changes excepted
